LHX3 CRISPR/Cas9 KO Plasmid (h): sc-404482
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- LHX3 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the LHX3 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: LHX3 Antibody (2C10): sc-293411
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LHX3 CRISPR/Cas9 KO Plasmid (h) | sc-404482 | 20 µg | $397.00 |
Overview
LHX3 (LIM homeobox 3) encodes a LIM-domain homeodomain transcription factor that coordinates lineage specification and terminal differentiation programs during embryogenesis. In the pituitary and nervous system, LHX3 regulates transcriptional networks controlling hormone-producing cell fate and motor neuron development through sequence-specific DNA binding and cofactor recruitment. Disruption of LHX3-dependent gene regulation perturbs developmental pathways governing anterior pituitary organogenesis and neuronal connectivity. Human genetic evidence links altered LHX3 function to combined pituitary hormone deficiency with variable neurodevelopmental phenotypes, making it a useful node for studying developmental transcriptional control.
LHX3 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the LHX3 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the LHX3 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the LHX3 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish LHX3 protein expression.
This CRISPR knockout system enables efficient generation of LHX3-deficient cell models for investigation of LHX3 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting LHX3 exon(s) critical for LHX3 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple LHX3 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by LHX3 CRISPR/Cas9 KO Plasmid (h) and LHX3 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the LHX3 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by LHX3 HDR Plasmid (h) and LHX3 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by LHX3 homology arms to support homology-directed repair at defined LHX3 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.